FDA Selects Casgevy, Orforglipron, Wegovy for 2nd Voucher Batch

The FDA reports six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program, bringing the total number of voucher recipients to 15.

• FDA selects six products following external applications and internal nominations from its review divisions:
  • Zongertinib for HER2 lung cancer
  • Bedaquiline for drug-resistant tuberculosis in young children
  • Dostarlimab for rectal cancer
  • Casgevy for sickle cell disease
  • Orforglipron for obesity and related conditions
  • Wegovy for obesity and related conditions
• National priority voucher holders will receive a decision within months
• NOTE: In Oct., FDA Gives National Priority Vouchers to Nine Sponsors

To contact the reporter on this story:
Janine ...